WeVote
Log In

Bill

Bill

SB 69

Relating to a statewide order issued by the commissioner of state health services authorizing a pharmacist to dispense ivermectin.

89th Legislature, 1st Called Session (2025) Introduced by Paul Bettencourt and 11 co-sponsors

Texas bill would let health commissioner authorize pharmacists to dispense ivermectin without prescriptions, expanding drug access but removing physician oversight.

Filed
#health&humanservicescommission(v0177) #healthcareproviders(i0387) #health--general(i0385) #medicine&prescriptiondrugs(s7338) #occupationalregulation--healthoccupations(i0540) #pharmacies&pharmacists(s1192) #pharmacy #texasstateboardof(v0022) #statehealthservices #departmentof(v0463)
0
WeVote Research Nonpartisan
Bill Summary · SB 69

Legislative bill overview

SB 69 would authorize Texas's Commissioner of State Health Services to issue a statewide order permitting pharmacists to dispense ivermectin without a prescription. The bill grants the commissioner discretionary power to establish conditions under which pharmacists can provide this medication directly to patients.

Why is this important

Ivermectin is an FDA-approved antiparasitic medication with established uses for certain parasitic infections, but it has become controversial due to off-label promotion for COVID-19 and other conditions lacking clinical evidence. This bill directly addresses pharmacy practice scope and access to medications, with implications for how Texas regulates drug dispensing and pharmacist authority.

Potential points of contention

  • Scientific evidence gap: Ivermectin lacks FDA approval and strong clinical evidence for most uses being promoted; pharmacist dispensing without prescription oversight raises concerns about misuse for unapproved conditions
  • Regulatory authority: The bill grants significant discretionary power to a single commissioner without legislative guardrails on dispensing criteria, dosage limits, or patient screening requirements
  • Medical oversight concerns: Over-the-counter pharmacy access removes physician evaluation, potentially eliminating important assessment of drug interactions, contraindications, and appropriate diagnosis before treatment

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.